Therapeutic effect of Tripterygium wilfordii on proteinuria associated with sirolimus in renal transplant recipients.
Sirolimus (SRL) is a potent immunosuppressive drug used to prevent acute allograft rejection after renal transplantation. Nevertheless, the occurrence of proteinuria has recently been recognized among patients on SRL-based therapy. The aim of this study was to investigate the therapeutic effects of Tripterygium wilfordii Hook F. (T II) on proteinuria associated with SRL in renal transplant recipients. According to accepting T II, 36 recipients were divided into 2 groups: T II group (n = 21) and valsartan group (n = 15). The T II group was administered 1 mg/kg/d, and the valsartan group, 80 mg twice per day for 12 months. Efficiency was then evaluated. Complete remission: proteinuria decreased by >50%; partial remission: proteinuria decreased by 20% to 50%; ineffective: proteinuria decreased by <20%. Upon 12-month follow-up, the total effective rates in the T II group and the valsartan group were 95.2% and 86.7% (P < .05), respectively. Twenty of 21 patients with proteinuria in the T II group were negative at 3-month follow-up with disappearance of edema. There were some adverse events that had greater incidence rates in the valsartan group compared with the T II group, such as hyperkalemia (26.7% vs 4.8%). We concluded that the application of T II markedly reduced proteinuria associated with SRL in renal transplant patients.
Ji
S M
SM
Research Institute of Nephrology, Department of Nephropathy, Jinling Hospital, Nanjing, China.
Li
L S
LS
Wen
J Q
JQ
Sha
G Z
GZ
Cheng
Z
Z
Cheng
D R
DR
Chen
J S
JS
Liu
Z H
ZH
D000328:Adult; D000959:Antihypertensive Agents / Q000627:therapeutic use; D002681:China; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000031:analogs & derivatives; D010936:Plant Extracts / Q000627:therapeutic use*; D011507:Proteinuria / Q000139:chemically induced / Q000188:drug therapy*; D020123:Sirolimus / Q000009:adverse effects*; D013777:Tetrazoles / Q000627:therapeutic use; D029757:Tripterygium; D014633:Valine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000068756:Valsartan; D055815:Young Adult
D000959:Antihypertensive Agents; D007166:Immunosuppressive Agents; D010936:Plant Extracts; D013777:Tetrazoles; D000068756:Valsartan; D014633:Valine; D009173:Mycophenolic Acid; D020123:Sirolimus